• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Mer­ck opens Vir­ginia plant to sup­port UNICEF deal for HPV vac­cines

4 years ago
Pharma
Manufacturing

Q&A: How Pen­n's CAR-T man­u­fac­tur­ing dis­cov­ery has dras­ti­cal­ly re­duced time­lines

4 years ago
Manufacturing

Fu­ji­film com­pletes ac­qui­si­tion of Atara's cell ther­a­py man­u­fac­tur­ing site near Los An­ge­les

4 years ago
Manufacturing

Law groups, pro­fes­sors lash out against Ther­mo Fish­er in suit over the 'im­mor­tal cell­s' of Hen­ri­et­ta Lacks

4 years ago
Pharma
Law

Asth­ma pa­tients are un­fa­mil­iar with bi­o­log­ic brands, but open to try — Phree­sia sur­vey

4 years ago
Pharma
Marketing

Neu­ro play­er Jazz Phar­ma­ceu­ti­cals dives in­to im­muno-on­col­o­gy, ink­ing cy­tokine pact with Were­wolf

4 years ago
Deals

RA, At­las-backed biotech spins up with $110M in pur­suit of pro­tein degra­da­tion via mol­e­c­u­lar glues

4 years ago
Financing
Startups

Fi­nal cov­er­age de­ci­sion for some Alzheimer's drugs is al­most here: What to re­mem­ber and what to ex­pect

4 years ago
Pharma
FDA+

In a one-two gut punch af­ter kid­ney drug CRL, Ake­bia slapped with par­tial hold and will lay off 42% of staff

4 years ago
R&D
FDA+

Flag­ship's Noubar Afeyan re­cruits the next CEO for one of its stealth biotech star­tups

4 years ago
People

Af­ter im­plod­ing three years ago, Aptinyx fol­lows a painful set­back with yet an­oth­er PhII fail­ure

4 years ago
R&D

Qual­i­ty met­rics for phar­ma man­u­fac­tur­ing is back in a big way, with FDA pledg­ing to 'ob­jec­tive­ly rate' firms

4 years ago
FDA+
Manufacturing

With an eye to 'non-ob­vi­ous bind­ing sites,' CBC Group launch­es pre­ci­sion med­i­cine play with $67M and ex-Ed­i­tas ex­ec ...

4 years ago
Financing
Startups

Two biotechs press for­ward with IPOs in a bid to stir mar­ket from hi­ber­na­tion

4 years ago
Financing

Surg­ing ahead in the RSV race, Pfiz­er buys out a PhII play­er in $525M M&A pact

4 years ago
Deals

Spot­ting a gem from transpa­cif­ic biotech, As­traZeneca pays $25M cash to pick up a pre­clin­i­cal bis­pe­cif­ic an­ti­body

4 years ago
Deals
China

Phar­ma IP in view as new USP­TO di­rec­tor Kathi Vi­dal wins Sen­ate con­fir­ma­tion

4 years ago
Pharma

Fol­low­ing $1.9B buy­out, Sanofi shut­ters Kad­mon's NY site and chops 25 staffers

4 years ago
Pharma

Catal­ent wins bid­ding war to take on UK's VMIC

4 years ago
Pharma
Manufacturing

Eu­rope holds off on a fourth Covid vac­cine shot for those un­der the age of 80

4 years ago
Coronavirus

Seres qui­et­ly dis­clos­es it has once again al­tered plans in ul­cer­a­tive col­i­tis

4 years ago
R&D

Co-founder of Flori­da phar­ma in­dict­ed af­ter mul­ti­state bac­te­r­i­al out­break at chil­dren's hos­pi­tals

4 years ago
Pharma
Manufacturing

John­son & John­son dri­ves pe­riph­er­al artery dis­ease aware­ness in new ‘Save Legs’ ini­tia­tive

4 years ago
Pharma
Marketing

Min­neso­ta judge nar­rows charges in class ac­tion suit against My­lan, phar­ma­cy ben­e­fit man­agers over EpiPen price hikes

4 years ago
Pharma
First page Previous page 553554555556557558559 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times